Evidence map›Paper›PMID 39526116›Full record

ReviewF1000Research2024

Clinical rationale for dietary lutein supplementation in long COVID and mRNA vaccine injury syndromes.

Anthony M Kyriakopoulos, Greg Nigh, Peter A McCullough, Stephanie Seneff

Abstract readReview
In one paragraph

Review in F1000Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anthony M KyriakopoulosDepartment of Research and Development, Nasco AD Biotechnology Laboratory, Piraeus, Greece.ORCID https://orcid.org/0000-0002-0749-0060
Greg NighNaturopathic Oncologist, Immersion Health, Portland, Oregon, USA.
Peter A McCulloughMcCullough Foundation, Dallas, Texas, USA.
Stephanie SeneffComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-8191-1049

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lutein, a plant-derived xanthophyl-carotenoid, is an exceptional antioxidant and anti-inflammatory constituent found in food. High dietary intake of lutein is beneficial against eye disease, improves cardiometabolic health, protects from neurodegenerative diseases, and is beneficial for liver, kidney, and respiratory health. Lutein protects against oxidative and nitrosative stress, both of which play a major role in long COVID and mRNA vaccination injury syndromes. Lutein is an important natural agent for therapeutic use against oxidative and nitrosative stress in chronic illnesses such as cardiovascular and neurodegenerative diseases and cancer. It can also potentially inhibit spike protein-induced inflammation. Rich dietary supplementation of lutein, naturally derived in non-biodegradable Extra Virgin Olive Oil (EVOO), can most optimally be used against oxidative and nitrosative stress during post-COVID and mRNA vaccination injury syndromes. Due to its high oleic acid (OA) content, EVOO supports optimal absorption of dietary lutein. The main molecular pathways by which the SARS-CoV-2 spike protein induces pathology, nuclear factor kappa-light-chain-enhancer activated B cells (NF-κB) and activated protein (AP)-1, can be suppressed by lutein. Synergy with other natural compounds for spike protein detoxification is likely.

Indexed as

COVID-19COVID-19 VaccinesDietary SupplementsLuteinCOVID-19 Drug TreatmentHumansmRNA VaccinesOlive OilOxidative StressPost-Acute COVID-19 SyndromeSpike Glycoprotein, CoronavirusCOVID-19 VaccinesLuteinmRNA VaccinesOlive OilSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Lutein; chronic illnesses; post-COVID and mRNA vaccination injury syndromes; inflammatory response; reactive oxygen species; extra virgin olive oil.

Identifiers

PMID39526116
PMCPMC11549548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.